Ferring Pharmaceuticals Inc. Application System
for Grants and Investigator-Initiated Trials

At Ferring, we not only strive to empower people to live healthy, fulfilling lives through pharmaceutical innovation, education and advocacy, we are also committed to supporting the advancement of medicine through research that leads to a better understanding of diseases, conditions and treatment strategies as well as healthcare professional education related to one of our therapeutic areas.

At this time, Ferring is considering funding related to the following therapeutic areas:

trials
mobile-trial-1

mobile-trial-4

mobile-trial-2

mobile-trial-3

 

Support is based on individual merit in accordance with established guidelines and policies and will not be provided to induce the provision of services or promote, sell or prescribe a Ferring product.

Please do not submit requests for exhibit/display booths, charitable contributions, promotional programs, membership fees, sponsorships, social events/entertainment, medical missions, ads, medication, equipment, tuition, or for non-faculty personnel or individual attendee expenses.

Grants

Ferring is committed to supporting independent educational programs and activities that contribute to the improvement of patient care in disease states in which we focus. We support programs such as continuing education for healthcare professionals, scientific conferences and patient education. The Ferring Grant Submission Guidelines outline our policies and requirements in order for a request to be considered.

Investigator-Initiated Trials

The mission and purpose of the Ferring Investigator-Initiated Trial Program is to provide support for investigator-initiated research that advances medical and scientific knowledge about Ferring’s products and generates promising medical therapeutics. The Ferring IIT Submission Guidelines outline our policies and requirements in order for a request to be considered.

Open Payments

The Federal Physician Payments Sunshine Act promotes transparency by requiring the discipline of financial relationships between drug manufacturers, investigators and study sites. Please refer to submission guidelines for specific reporting requirements.

Thank you for considering Ferring as a source of support for your educational initiatives and research interests.

This site contains material about Ferring Pharmaceuticals Inc. (hereinafter "Ferring") and its various products that may be of interest to Ferring's employees and customers, as well as to members of the health care community and the general public. Please feel free to browse this web site. Your access and use of the information contained herein is subject to the following terms and conditions and all applicable laws. By accessing and browsing this web site, you accept, without limitation or qualification, these terms and conditions and acknowledge that they supersede any other agreement between you and Ferring.

All information on this site is intended for US audiences only.

CERVIDIL, CLENPIQ, ENDOMETRIN, EUFLEXXA, FIRMAGON, MENOPUR, NOCDURNA, NOVAREL, and ZOMACTON are registered trademarks of Ferring B.V. INVOCELL is a registered trademark of INVO BioScience. ORTIKOS is a trademark of Sun Pharma Global FZE.

©2008-2020 Ferring Pharmaceuticals.  US-CORP-2000062